Generic Medicines: Solutions for a Sustainable Drug Market?
Systematic Review of Drug Administration Costs and Implications for Biopharmaceutical Manufacturing
Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
Does the Type of Provider and the Place of Residence Matter in the Utilization of Prenatal Ultrasonography? Evidence from Canada
Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US
Preferences for Colorectal Cancer Screening Techniques and Intention to Attend: a Multi-Criteria Decision Analysis
Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
Private Expenditures on Brand Name Prescription Drugs after Generic Entry
Economic Evaluation of Cardio inCode®, a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment
Evolutions in Both Co-Payment and Generic Market Share for Common Medication in the Belgian Reference Pricing System
Comment on: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
Authors' Reply to Liedgens and Henske: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”